3
ALL3
LabcorpYear
3
ALL1
20241
20221
2021DEALS // DEV.
3
ALL1
Deals2
DevelopmentsCountry
3
ALL3
U.S.A3
ALL1
Amgen Inc1
Inapplicable1
Xcell BiosciencesTherapeutic Area
3
ALL1
Genetic Disease2
OncologyStudy Phase
3
ALL2
Approved FDF1
PreclinicalDeal Type
3
ALL1
Collaboration2
InapplicableProduct Type
3
ALL1
Cell and Gene therapy1
Other Small Molecule1
UndisclosedDosage Form
3
ALL1
Intravenous Infusion1
Oral1
Oral TabletLead Product
3
ALL1
Fidanacogene elaparvovec1
Sotorasib1
UndisclosedTarget
3
ALL1
KRAS G12C2
UndisclosedLead Product(s) : Fidanacogene elaparvovec
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Labcorp Receives FDA Approval for Companion Diagnostic for Hemophilia B Gene Therapy
Details : The FDA has approved its nAbCyte Anti-AAVRh74var HB-FE Assay, a companion diagnostic to determine patient eligibility for treatment with Beqvez (fidanacogene elaparvovec).
Product Name : Beqvez
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 29, 2024
Lead Product(s) : Fidanacogene elaparvovec
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Xcell Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Through the collaboration, Labcorp and Xcellbio will work on a series of projects focused on improving the safety and efficacy of cell and gene therapies (CGTs). s. The projects included in the collaboration will use Xcellbio’s AVATAR incubator system ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 19, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Xcell Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Sotorasib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Labcorp Launches Companion Diagnostic for Amgen’s Newly-approved Lung Cancer Therapy
Details : Using the lung biopsy specimen, the assay identifies whether a patient with NSCLC has a specific mutation in the KRAS gene and is eligible for treatment with LUMAKRAS™ (sotorasib) which was developed by Amgen.
Product Name : Lumakras
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2021
Lead Product(s) : Sotorasib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable